Briacell Therapeutics
BCTX
19 hedge funds and large institutions have $6.38M invested in Briacell Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 6 closing their positions.
307% more call options, than puts
Call options by funds: $912K | Put options by funds: $224K
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 0.11% → 0.09% (-0.02%)
17% less funds holding
Funds holding: 23 → 19 (-4)
57% less capital invested
Capital invested by funds: $15M → $6.38M (-$8.6M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$294K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$126K |
| 3 |
OBWG
Onyx Bridge Wealth Group
Tarrytown,
New York
|
+$73.3K |
| 4 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$62.8K |
| 5 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
+$23.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$1.56M |
| 2 |
Morgan Stanley
New York
|
-$389K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$184K |
| 4 |
MG
Marex Group
London,
|
-$176K |
| 5 |
N
Natixis
Paris,
France
|
-$130K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ASN
26
Advisory Services Network
Atlanta,
Georgia
| – | -$1.75K | -2 | Closed |
|
27
UBS Group
Zurich,
Switzerland
| – | -$88 | – | – |
|
BCTX Hedge Fund Activity: Q1 2024 in Review
19 of the 6,944 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q1 2024, worth a combined $6.38M — down 57% from $15M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BCTX and 2 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Bank of Montreal, adding an estimated $294K. The largest seller was Wasatch Advisors, exiting entirely with an estimated $1.56M sold.
- 19 institutional investors held Briacell Therapeutics (BCTX) as of Q1 2024, down from 23 in Q4 2023.
- Funds reported $6.38M of Briacell Therapeutics stock for Q1 2024, down 57% quarter-over-quarter.
- 2 funds opened new Briacell Therapeutics positions in Q1 2024 and 6 closed out, a net change of -4 holders.
- The largest Briacell Therapeutics buyer in Q1 2024 was Bank of Montreal, an estimated $294K added.
- The largest Briacell Therapeutics seller in Q1 2024 was Wasatch Advisors, an estimated $1.56M sold.
Based on aggregated 13F filings for Q1 2024.